Список проголосовавших за комментарий " Mateon Therapeutics initiated with a Buy at Maxim Group; tgt $2 (0.39)Maxim Group initiates MATN with a Buy and price target of $2. The anti-angiogenic (AA) market generates over $15B annually (Avastin=$6B). Recall that Avastin is approved not just for ovarian cancer, but also glioblastoma, lung cancer, and other indications. Thus, if a CA4P combination with Avastin is successful, even just slightly (beginning with OC), there is upside at the current valuation given the market size, in firm's view."